X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, Worldwide Clinical Trials will support the Company’s planned Phase 1 trial with ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor in development for the treatment of chemotherapy-induced peripheral neuropathy (CIPN).
Lead Product(s): ART26.12
Therapeutic Area: Neurology Product Name: ART26.12
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Artelo Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 08, 2024
Details:
Under the partnership, Worldwide Clinical Trials will support clinical developments of CYB003, an investigational proprietary deuterated analog of psilocybin, currently in Phase 2 trial for the treatment of major depressive disorder.
Lead Product(s): Deuterated Psilocybin Analog
Therapeutic Area: Psychiatry/Psychology Product Name: CYB003
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cybin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 26, 2023
Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.
Lead Product(s): ACI-24.060
Therapeutic Area: Neurology Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: AC Immune
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Neurotrope has entered into a services agreement with Worldwide Clinical Trials to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatment of moderately severe Alzheimer's disease.
Lead Product(s): Bryostatin-1
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurotrope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
